Federal Service for Intellectual Property (Russia)

Immutep Quarterly Activities Report

Retrieved on: 
Friday, April 29, 2022
ASCO, Public, Family, GMP, Time, Patent, Institute, FDA, Federal Service for Intellectual Property (Russia), Novartis, Paclitaxel, Cancer, Kinetics, Australian Securities Exchange, NASDAQ, Nivolumab, Phase, EMA, European Medicines Agency, Antibody, US Foods, Patient, GLOBE, Method, Central Statistics Office (India), Survival, Company, Intellectual property, LAG-3, LAG525, Infection, INN, HNSCC, Institutional review board, ASX, IMM, Technology, APC, Head, US, Autoimmune disease, Board, Carboplatin, Research and development, IKF, Annual general meeting, AIPAC, Development, Pembrolizumab, Russia, Friends, Society, MBC, Breast cancer, Cryptocurrency, Pharmaceutical industry, Vaccine, Research, NSCLC, Immutep

Immutep will report new biomarker and multivariate analysis data from the Phase IIb AIPAC trial in a poster presentation at ESMOs Breast Cancer Congress in May 2022.

Key Points: 
  • Immutep will report new biomarker and multivariate analysis data from the Phase IIb AIPAC trial in a poster presentation at ESMOs Breast Cancer Congress in May 2022.
  • In March 2022, Immutep received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical development program for efti in MBC.
  • The net cash used in G&A activities in the quarter was $1.6 million compared to $0.2 million in Q2 FY22.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Wolters Kluwer Legal Experts Offer Analysis on a Range of Business, Financial, and Global Impacts as Russia's Invasion of Ukraine Continues

Retrieved on: 
Friday, March 25, 2022
Linda, Risk, OFAC, NATO, Euronext, Office of Foreign Assets Control, Computer security, Leadership, Financial Crimes Enforcement Network, Eurasian Patent Organization, Compliance, Privacy, Euronext Amsterdam, LINK, SEC, CISA, Risk management, AEX, EAPO, ADR, ADR Institute of Alberta, USPTO, American, WKL, Technology, Interview, Federal Service for Intellectual Property (Russia), Intellectual property, Disclosure, Time, Consolidated Appropriations Act, 2021, Solution, Accounting, IP, Financial adviser, Weapon, Cryptocurrency, Medical device, Security (finance)

NEW YORK, March 25, 2022 /PRNewswire/ -- 

Key Points: 
  • The SEC also proposed rules to enhance and standardize disclosure regarding cybersecurity risk management, strategy, governance, and incident reporting.
  • Tony Foley, Privacy & Cybersecurity Legal Analyst at Wolters Kluwer Legal & Regulatory U.S.
    Thomas Long, Senior Intellectual Property Legal Analyst at Wolters Kluwer Legal & Regulatory U.S.
    Mark Nelson, Senior Securities Legal Analyst at Wolters Kluwer Legal & Regulatory U.S.
    Katalina Bianco, Senior Banking and Finance Legal Analyst at Wolters Kluwer Legal & Regulatory U.S.
    John Pachkowski, Senior Banking and Finance Legal Analyst at Wolters Kluwer Legal & Regulatory U.S.
  • Contact: To arrange an interview with a Wolters Kluwer Legal & Regulatory U.S. legal expert on this or any other related topics, please contact Linda Gharib at [email protected] .
  • About Wolters Kluwer Legal & Regulatory U.S.
    Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors.

BioCorRx Provides Business Update for the Third Quarter of 2021

Retrieved on: 
Tuesday, November 16, 2021
NDA, USPTO, Irisys, Drug development, Naltrexone, CDMO, National Institute on Drug Abuse, Substance abuse, Clinical trial, Security (finance), Food and Drug Administration, CEO, Opioid use disorder, CGMP, National, Food, CA, Federal Service for Intellectual Property (Russia), National Institute, NIDA, Cognitive behavioral therapy, CBT, U.S. Securities and Exchange Commission, Company, GLOBE, Solution, Nutritionist, OTCQB, Patent, NIH, FDA, CFO, Pharmaceutical industry

ANAHEIM, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the Company), a developer and provider ofinnovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2021 and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the Company), a developer and provider ofinnovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2021 and reported on recent corporate developments.
  • This is a major milestone as this funding is non-dilutive and substantially covers our financial costs as we move through the FDA approval process.
  • In addition, we expanded our agreement with IriSys LLC, the San Diego-based contract development and manufacturing organization (CDMO) that was recently acquired by Recro.
  • BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders.

BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant

Retrieved on: 
Thursday, October 7, 2021
NIDA, Company, Nutritionist, Patent, National, National Institute, Development, Drug development, GLOBE, Opioid use disorder, Clinical trial, CFO, Population, CBT, FDA, OUD, RFA, Naltrexone, Federal Service for Intellectual Property (Russia), CEO, Solution, NIH, OTCQB, National Institute on Drug Abuse, Cognitive behavioral therapy, Pharmaceutical industry

ANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the Company), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the Russian Patent Office (Rospatent) for a biodegradable implant including naltrexone.

Key Points: 
  • ANAHEIM, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the Company), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the Russian Patent Office (Rospatent) for a biodegradable implant including naltrexone.
  • Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., stated, We continue our plan of pursuing patents internationally, and maintain our commitment of addressing the opioid crisis worldwide.
  • Russia is suffering from serious and problematic drug consumption and a growing public health crisis with approximately 6% of the population using drugs .
  • Filing this patent application is another key milestone in our intellectual property strategy to build a global patent portfolio, as we advance towards commencing our first-in-human clinical trial of BICX104.